1. Wilson JW, Tsukayama DT. Extensively drug-resistant tuberculosis: principles of resistance, diagnosis, and management. Mayo Clin Proc 2016; 91:482-95.
2. Ruan Q, Liu Q, Sun F, Shao L, Jin J, Yu S, et al. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerg Microb Infect 2016; 5:e12.
3. Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 2015; 62:418-30.
4. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. T Int J Tuberc Lung Dis 2008; 12:869-77.
5. Matteelli A, Roggi A, Carvalho AC. Extensively drug-resistanttuberculosis: epidemiology and management. Clin Epidemiol 2014; 6:111-8.
6. Chang KC, Yew WW. Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: update 2012. Respirology 2013; 18:8-21.
7. Gillespie SH. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev 2016; 25:19-28.
8. Daley CL, Caminero JA. Management of multidrug resistant tuberculosis. Semin Respir Crit Care Med 2013; 34:44-59.
9. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67:2077-99.
10. De Souza MV, Vasconcelos TR, Almeida MV, Cardoso SH. Fluoroquinolones: an important class of antibiotics against tuberculosis. Curr Med Chem 2006; 13:455-63.
11. Yew WW, Koh WJ. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? Korean J Intern Med 2016; 31:15-29.
12. Ginsberg A, Spigelman M. New drugs for tuberculosis. Tuberculosis: The Essentials; 2005.
13. Ignatyeva O, Balabanova Y, Nikolayevskyy V, Koshkarova E, Radiulyte B, Davidaviciene E, et al. Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries. Tuberculosis 2015; 95:581-8.
14. Bulloch MN. Incorporation of fluoroquinolones in the tuberculosis treatment regimen. Int J Med Biol Front 2013; 19:1.
15. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin 2007; 23:1403-13.
16. Bacci C, Galli L, de Martino M, Chiappini E. Fluoroquinolones in children: update of the literature. J Chemother 2015; 27:257-65.

17. Principi N, Esposito S. Appropriate use of fluoroquinolones in children. Int J Antimicrob Agents 2015; 45:341-6.
18. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respirat J 2012; 25:1-24.
19. De Souza MV, Vasconcelos TR, Almeida MV, Cardoso SH. Fluoroquinolones: an important class of antibiotics against tuberculosis. Curr Med Chem 2006; 13:455-63.
20. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67:2077-99.
21. Lowther J, Bryskier A. Fluoroquinolones and tuberculosis. Exp Opin Investigat Drugs 2002; 11:233-58.
22. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61:9-18.
23. Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009; 48:1361-3.
24. O'brien RJ. Development of fluoroquinolones as first-line drugs for tuberculosis—at long last! Am J Respirat Crit Care Med 2003; 168:1266-8.
25. Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis 2015; 95:229-45.
26. Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive). New York: The Cochrane Library; 2013.
27. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberculosis Lung Dis 1998; 2:265-71.
28. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respirat J 2012; 25:1-24.
29. Principi N, Esposito S. Appropriate use of fluoroquinolones in children. Int J Antimicrob Agents 2015; 45:341-6.
30. Ruan Q, Liu Q, Sun F, Shao L, Jin J, Yu S, et al. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerg Microb Infect 2016; 5:e12.
31. Lee H, Jeong BH, Park HY, Jeon K, Huh HJ, Lee NY, et al. Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2016; 60:471-7.
32. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432-42.
33. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-7.
34. O'brien RJ. Development of fluoroquinolones as first-line drugs for tuberculosis—at long last! Am J Respirat Crit Care Med 2003; 168:1266-8.
35. Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis—a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014; 26:149-53.
36. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Inf Dis 2003; 37:1448-52.
37. Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother 2011; 55:5421-9.

38. Yew WW, Koh WJ. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? Korean J Intern Med 2016; 31:15-29.
39. Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis 2015; 32:118-23.
40. Bulloch MN. Incorporation of fluoroquinolones in the tuberculosis treatment regimen. Int J Med Biol Frontiers 2013; 19:1.
41. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberculosis Lung Dis 1998; 2:265-71.
42. Rodrıguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17:229-31.
43. Kang YA, Shim TS, Koh WJ, Lee SH, Lee CH, Choi JC, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thor Soc 2016; 13:364-70.
44. O'brien RJ. Development of fluoroquinolones as first-line drugs for tuberculosis—at long last! Am J Respirat Crit Care Med 2003; 168:1266-8.
45. Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis 2015; 95:229-45.
46. Anand RS, Somasundaram S, Doble M, Paramasivan CN. Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis. BMC Struct Biol 2011; 11:47.
47. Ruiz-Serrano MJ, Alcalá L, Martínez L, Díaz M, Marín M, González-Abad MJ, et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of mycobacterium tuberculosissusceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44:2567-8.
48. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54:4765-71.
49. Rodrıguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17:229-31.
50. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780-2.
51. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-7.
52. Ssengooba W, Meehan CJ, Lukoye D, Kasule GW, Musisi K, Joloba ML, et al. Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. Infect Genet Evol 2016; 40:8-16.
53. Li D, Wang T, Shen S, Cheng S, Yu J, Zhang Y, et al. Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis. PloS One 2015; 10:e0145066.
54. Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40:1768-74.
55. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respirat Crit Care Med 2003; 168:1342-5.

56. Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother 2015; 59:4026-30.
57. Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci 2016; 113:E839-46.
58. Mayer C, Takiff H. The molecular genetics of fluoroquinolone resistance in Mycobacterium tuberculosis. Molecular genetics of mycobacteria. 2nd ed. New York: American Society of Microbiology; 2014.
59. Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, Reitter D, et al. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:4524-9.
60. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003; 47:3117-22.
61. Lee WY, Ling M, Anderson G, Achawal S, Thaker HK. Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. J Med Microbiol 2011; 60:1550-2.
62. Fouad M, Gallagher JC. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Ann Pharmacother 2011; 45:1439-44.
63. Lee WY, Ling M, Anderson G, Achawal S, Thaker HK. Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. J Med Microbiol 2011; 60:1550-2.
64. Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive). New York: The Cochrane Library; 2013.
65. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015; 385:1738-47.
66. te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 2015; 45:496-503.
67. Lata M, Sharma D, Deo N, Kumar Tiwari P, Bisht D, et al. Proteome analysis of ofloxacin and moxifloxacin induced Mycobacterium tuberculosis isolates by proteomic approach. Protein Pept Lett 2015; 22:362-71.
68. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54:4765-71.
69. Gillespie SH. The role of moxifloxacin in tuberculosis therapy. Eur Respirat Rev 2016; 25:19-28.
70. Ssengooba W, Meehan CJ, Lukoye D, Kasule GW, Musisi K, Joloba ML, et al. Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. Infect Genet Evol 2016; 40:8-16.
71. Willby M, Sikes RD, Malik S, Metchock B, Posey JE. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59:5427-34.
72. Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, Silva JT, Muñoz-Sanz A, Muñoz P, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with

a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis 2015; 60:1642-9.
73. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; 1:CD004795.
74. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; 1:CD004795.
75. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102:1815-8.
76. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61:9-18.
77. Alangaden GJ, Bone SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25:1213-21.
78. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al. Randomized controlled trial of a drug regimen that includes ciproftoxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22:827-33.
79. te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 2015; 45:496-503.
80. Yew WW, Piddock LJ, Li MS, Lyon D, Chan CY, Cheng AF. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34:343-51.
81. Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, Ramsay AR, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am J Respirat Crit Care Med 1993; 148:1547-51.
82. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993; 104:1194-8.
83. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39:1341-4.
84. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117:744-51.
85. Sotgiu G, Migliori GB. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther 2015; 32:144-8.
86. Tseng YT, Chuang YC, Shu CC, Hung CC, Hsu CF, Wang JY. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Crit Care 2012; 16:R207.
87. Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, et al. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB. J Antimicrob Chemother 2015; 71:333-8.
88. Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, et al. Association between regimen composition and treatment response in patients with multidrug-resistant tuberculosis: a prospective cohort study. PLoS Med 2015; 12:e1001932.
89. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999; 58:19-22.
90. Lowther J, Bryskier A. Fluoroquinolones and tuberculosis. Exp Opin Investigat Drugs 2002; 11:233-58.
91. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respirat J 2008; 31:904-5.
92. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995–2003. J Antimicrob Chemother 2005; 56:1058-62.

93. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PloS One 2012; 7:e39754.
94. Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci 2016; 113:E839-46.
95. Ahmad N, Javaid A, Sulaiman SA, Ming LC, Ahmad I, Khan AH. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis 2016; 20:41-7.
96. Fox GJ, Oxlade O, Menzies D. Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis. Am J Respirat Crit Care Med 2015; 192:229-37.
97. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40:885-8.
98. Lee H, Jeong BH, Park HY, Jeon K, Huh HJ, Lee NY, et al. Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2016; 60:471-7.
99. Trieu L, Proops DC, Ahuja SD. Moxifloxacin prophylaxis against MDR TB, New York, New York, USA. Emerg Infect Dis 2015; 21:500.
100. Zvada SP, Denti P, Sirgel FA, Chigutsa E, Hatherill M, Charalambous S, et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob Agents Chemother 2014; 58:503-10.
101. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54:4765-71.
102. Yew WW, Kwan SY, Ma WK, Khin MA, Chan PY. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26:227-36.
103. Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res 1992; 12:173-8.
104. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al. Randomized controlled trial of a drug regimen that includes ciproftoxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22:827-33.
105. Yew WW, Chau CH, Tupasi TE, Singla R, Gupta S, Gupta R, et al. Utility of fluoroquinolones in multidrug-resistant tuberculosis (MDR-TB)-a balanced view? Int J Tuberc Lung Dis 2002; 6:174-5.
106. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PloS One 2012; 7:e39754.
107. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, et al. Diagnostic performance of the new version (v2. 0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 2015; 53:2961-9.
108. Ahmad N, Javaid A, Sulaiman SA, Ming LC, Ahmad I, Khan AH. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis 2016; 20:41-7.

109. Surcouf C, Heng S, Pierre-Audigier C, Cadet-Daniel V, Namouchi A, Murray A, et al. Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes. BMC Infect Dis 2011; 11:255.
110. Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health 2014; 7:75-91.
111. Kamal SM, Hossain A, Sultana S, Begum V, Haque N, Ahmed J, et al. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int J Tuberc Lung Dis 2015; 19:151-6. .
112. Mirza IA, Khan FA, Khan KA, Satti L, Ghafoor T, Fayyaz M. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin). J Coll Physicians Surg Pak 2015; 25:337-41.
113. Shen GH, Tsao TC, Kao SJ, Lee JJ, Chen YH, Hsieh WC, et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 2012; 39:201-5.
114. Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009; 48:1361-3.
115. Van Der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis. Epidemiol Infect 2015; 143:960-5.
116. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61:903-8.
117. Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis—a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014; 26:149-53.
118. Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis—a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014; 26:149-53.
119. Chang KC, Yew WW, Chan RC. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2010; 65:1551-61.
120. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, et al. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 2012; 56:1990-6.
121. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, et al. Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis. J Clin Microbiol 2016; 54:727-33.
122. Coeck N, de Jong BC, Diels M, de Rijk P, Ardizzoni E, Van Deun A, et al. Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis. J Antimicrob Chemother 2016; 71:1233-40.
123. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 2013; 62:108-13.

124. Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, et al. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and-sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. J Antibiot 2015; 68:63.
125. Chopra S, Matsuyama K, Tran T, Malerich JP, Wan B, Franzblau SG, et al. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 67:415-21.
126. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67:819-31.
127. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39:1700-3.
128. Kontsevaya I, Mironova S, Nikolayevskyy V, Balabanova Y, Mitchell S, Drobniewski F. Evaluation of two molecular assays for rapid detection of Mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and-multidrug-resistance settings. J Clin Microbiol 2011; 49:2832-7.
129. Anand RS, Somasundaram S, Doble M, Paramasivan CN. Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis. BMC Struct Biol 2011; 11:47.
130. An DD, Duyen NT, Lan NT, Ha DT, Kiet VS, Chau NV, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother 2009; 53:4835-9.
131. Chang KC, Yew WW, Sotgiu G. Clinical research in the treatment of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis 2015; 19:1417-27.
132. Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One 2015; 10:e0120470.
133. Zhu C, Zhang Y, Shen Y, Siu GK, Wu W, Qian X, et al. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. Diag Microbiol Infect Dis 2012; 73:260-3.
134. Van Der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis. Epidemiol Infect 2015; 143:960-5.